OneAscent Financial Services LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

OneAscent Financial Services LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 27.9% during the 4th quarter, HoldingsChannel reports. The firm owned 12,169 shares of the company’s stock after purchasing an additional 2,656 shares during the period. OneAscent Financial Services LLC’s holdings in Johnson & Johnson were worth $1,760,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Bryce Point Capital LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $497,000. WESCAP Management Group Inc. raised its holdings in Johnson & Johnson by 56.1% during the fourth quarter. WESCAP Management Group Inc. now owns 4,453 shares of the company’s stock worth $644,000 after purchasing an additional 1,600 shares in the last quarter. Private Portfolio Partners LLC boosted its holdings in Johnson & Johnson by 9.5% in the 4th quarter. Private Portfolio Partners LLC now owns 11,023 shares of the company’s stock valued at $1,594,000 after purchasing an additional 957 shares in the last quarter. Intrepid Capital Management Inc. raised its stake in shares of Johnson & Johnson by 15.2% during the 4th quarter. Intrepid Capital Management Inc. now owns 8,198 shares of the company’s stock worth $1,186,000 after buying an additional 1,080 shares in the last quarter. Finally, Kesler Norman & Wride LLC lifted its holdings in shares of Johnson & Johnson by 1.7% in the 4th quarter. Kesler Norman & Wride LLC now owns 52,051 shares of the company’s stock valued at $7,528,000 after buying an additional 877 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 7.6 %

Shares of JNJ opened at $153.25 on Wednesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company’s fifty day moving average is $159.16 and its two-hundred day moving average is $155.99. The firm has a market cap of $369.30 billion, a PE ratio of 23.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 earnings per share. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s payout ratio is currently 74.59%.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Finally, Bank of America raised their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $171.33.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.